Efficacy of Topical Cysteamine in Nephropathic Cyctinosis
NCT ID: NCT02766855
Last Updated: 2016-05-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
26 participants
INTERVENTIONAL
2004-01-31
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis
NCT00001213
New Cysteamine Eye Drops Formulation to Treat Corneal Crystals in Cystinosis
NCT00001736
Randomized Study of New Formulation Ophthalmic Cysteamine Hydrochloride for Corneal Cystine Accumulation in Patients With Cystinosis
NCT00010426
Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
NCT02688556
Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers
NCT00335114
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cysteamine eye drops
Patients used cysteamine eye drops every 2 hours while awake to both eyes.
Cysteamine
Patients were asked to use topical cysteamine 0.55% eye drops every 2 hours while awake to both eyes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cysteamine
Patients were asked to use topical cysteamine 0.55% eye drops every 2 hours while awake to both eyes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* leucocyte cystine concentration level of more than 2.0 nmol half-cystine/ mg protein
* clinical evidence of tissue deposition of cystine and tissue damage due to cystinosis
Exclusion Criteria
8 Months
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Eye Center and The Eye Foundation for Research in Ophthalmology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Samir S. Shoughy, MD, FRCS (Glasg.)
Ophthamolgist, uveitis, Cornea & External Eye Disease
References
Explore related publications, articles, or registry entries linked to this study.
Al-Hemidan A, Shoughy SS, Kozak I, Tabbara KF. Efficacy of topical cysteamine in nephropathic cystinosis. Br J Ophthalmol. 2017 Sep;101(9):1234-1237. doi: 10.1136/bjophthalmol-2016-309278. Epub 2017 Jan 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TEC C123
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.